Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WEZLANA vs ESIMIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Treatment of active psoriatic arthritis in adults
Hypertension (to lower blood pressure, not for initial therapy)
IV: 500 mg every 12 hours over 60 minutes.
5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
2.3 ± 0.4 hours; prolonged in renal impairment (up to 6.5 hours in severe cases).
WEZLANA is a monoclonal antibody expected to be degraded into small peptides and amino acids via catabolic pathways; no specific metabolic enzymes involved.
Olmesartan: undergoes hepatic ester hydrolysis to active metabolite, not metabolized by CYP450 system. Amlodipine: extensively metabolized in liver via CYP3A4. Hydrochlorothiazide: not significantly metabolized.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Primarily renal (>90% as unchanged drug); biliary/fecal <10%.
95% bound to albumin.
40-50% bound to albumin.
0.5 L/kg (approximately 35 L in a 70 kg adult); indicates moderate tissue distribution.
1.5-2.0 L/kg; suggests extensive tissue distribution.
Oral: 85% (due to first-pass metabolism); Intravenous: 100%.
Oral: 55-65% due to first-pass metabolism.
GFR ≥60 m L/min: no adjustment; GFR 30-59: 250 mg every 12 hours; GFR 15-29: 250 mg every 24 hours; GFR <15: 250 mg every 48 hours.
e GFR 30-89 m L/min: no adjustment. e GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
2-12 years: 10 mg/kg IV every 12 hours (max 500 mg/dose); ≥12 years: same as adult.
Not approved for pediatric use; safety and efficacy not established.
No specific dose adjustment except based on renal function; monitor for prolonged QT interval.
Start at 2.5 mg once daily due to increased sensitivity and risk of adverse effects.
No FDA black box warning.
Discontinue as soon as possible when pregnancy is detected. Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Increased risk of infections, including serious infections,Hypersensitivity reactions,Potential for immunogenicity and loss of efficacy,Pre-treatment evaluation for tuberculosis infection recommended,Avoid use of live vaccines during treatment
Fetal toxicity (see black box warning),Hypotension in volume-depleted patients,Monitor renal function; may increase serum creatinine and BUN,Electrolyte disturbances (hypokalemia, hyponatremia, hypercalcemia),Exacerbation of angina or acute MI (especially with rapid dose increase of amlodipine),Acute angle-closure glaucoma (with HCTZ),Systemic lupus erythematosus exacerbation (with HCTZ),Metabolic acidosis (with HCTZ),Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min)
History of hypersensitivity to WEZLANA or any of its excipients,Clinically significant active infection
Hypersensitivity to any component,Anuria (due to HCTZ),Concomitant use with aliskiren in patients with diabetes
No significant food interactions identified. Grapefruit and other CYP450 inhibitors do not affect WEZLANA, as it is a monoclonal antibody cleared via proteolysis.
Food may delay absorption; take on an empty stomach for best results. Avoid acidic beverages (e.g., orange juice) within 30 minutes of dosing. No significant food restrictions but a low-acid diet may help symptom control.
First trimester: Potential for major congenital malformations, including neural tube defects, cardiac anomalies, and craniofacial defects based on animal studies and limited human data. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Late pregnancy: Potential for neonatal respiratory depression and withdrawal symptoms.
Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some retrospective studies. In the second and third trimesters, use may be associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of neonatal irritability. Overall, use only if clearly needed and after first trimester.
Not recommended during breastfeeding due to high lipid solubility and potential for infant toxicity. M/P ratio unknown; expected to concentrate in breast milk.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~2.5-3.5). It may reduce milk production, especially with chronic use. The relative infant dose is estimated at 2-5% of maternal weight-adjusted dose. Caution is advised; monitor infant for irritability, sleep disturbances, and feeding problems.
Due to increased volume of distribution and enhanced renal clearance in pregnancy, consider increasing dose by 20-30% in second and third trimesters. Monitor therapeutic drug levels to guide adjustments.
No standard dose adjustments are recommended, but due to increased renal clearance in pregnancy, therapeutic effects may be reduced. Use the lowest effective dose for the shortest duration. Avoid sustained-release formulations in pregnancy due to unpredictable absorption.
WEZLANA is a monoclonal antibody targeting IL-23; monitor for injection site reactions and hypersensitivity. Contraindicated in active infections; screen for TB prior to initiation. Do not administer live vaccines during treatment.
ESIMIL (esomeprazole) is a proton pump inhibitor (PPI) used for acid-related disorders. Onset of action is rapid, but maximal acid suppression occurs after 5-7 days. Best taken before breakfast for optimal effect. Avoid co-administration with clopidogrel due to reduced efficacy. Monitor magnesium levels with prolonged use, especially in patients taking diuretics or digoxin. Consider calcium and vitamin D supplementation to mitigate osteoporosis risk.
Report any signs of infection, such as fever, cough, or skin redness.,Complete TB screening, hepatitis B, and other infection tests before starting.,Avoid live vaccines (e.g., MMR, varicella) during and for 6 months after treatment.,Store WEZLANA in the refrigerator, do not freeze; protect from light.,Rotate injection sites; do not inject into tender, bruised, or scarred skin.
Take this medication 30-60 minutes before a meal, preferably breakfast.,Swallow capsules whole; do not crush or chew.,Do not take with other acid reducers unless directed.,Report symptoms of severe diarrhea, bone pain, or muscle cramps.,Avoid alcohol and spicy foods that may worsen symptoms.,Long-term use may increase risk of fractures; ensure adequate calcium intake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WEZLANA vs ESIMIL, answered by our medical review team.
WEZLANA is a Unknown that works by WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.. ESIMIL is a Unknown that works by Fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide. Olmesartan is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal tubule.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WEZLANA and ESIMIL depend on the specific clinical indication. These are both Unknown agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WEZLANA is: IV: 500 mg every 12 hours over 60 minutes.. The standard adult dose of ESIMIL is: 5 mg orally once daily, may increase to 10 mg once daily after 2-4 weeks if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WEZLANA and ESIMIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WEZLANA is classified as Category C. First trimester: Potential for major congenital malformations, including neural tube defects, cardiac anomalies, and craniofacial defects based on animal studies and limited human . ESIMIL is classified as Category C. Esimil (pseudoephedrine) is classified as FDA Pregnancy Category C. In the first trimester, there is limited data but a potential risk of gastroschisis has been suggested in some r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.